Welcome
Support Centre
21 November 2008 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
UKCTG
mental health register
archived registers
all registers
tips on searching
 
Registration
submit trials
 
Information
about mRCT
mRCT FAQs
data items
memorandum
contributors

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
Is colour duplex ultrasound more sensitive than clinical assessment in predicting early failure of primary arteriovenous fistulae (AVF)?
Source of recordUK Clinical Trials Gateway
ISRCTNISRCTN54883610
Date ISRCTN assigned28/09/2007
Local reference number(s)N0234190027
Public titleIs colour duplex ultrasound more sensitive than clinical assessment in predicting early failure of primary arteriovenous fistulae (AVF)?
Scientific title
AcronymN/A
Disease/condition/study domainCardiovascular: Primary arteriovenous fistula
Study hypothesis1. Principal question: is ultrasound surveillance of primary AVF necessary or is clinical assessment adequate
for primary AVF survival?
2. Principal objective: to define a method to reduce early primary AVF failure.
Design/methodologyRandomised controlled trial
Research ethics reviewNot provided at time of registration
Countries of trialUnited Kingdom
Participants - inclusion criteriaBoth groups will be recruited in the same way through the renal consultants and will be randomly allocated to
one of two groups. It is predicted that the sample size will be no more than 144 patients in the first year as this is the predicted maximum number of patients requiring primary AVF in this timescale. It is predicted that the final number of patients required for the sample will be approximately 50 per group as a result of a retrospective study performed previously by Robbin et al (2002).

Inclusion criteria:
1. Adult patient requiring primary AVF
2. No previous AVF or dialysis via central line
3. Upper limb vein/artery suitable for AVF formation
4. The patients' eGFRml/min/1.73m^2 must be greater than 15 to minimise likelihood of access being required
before maturation of primary AVF
Participants - exclusion criteria1. Children (<18 years old)
2. Those patients unable to give consent
3. AVG formation required
4. Previous AVF
5. Previous access via central line
6. Patients with failing transplant
7. Patients undergoing peritoneal dialysis
Patient information material
Anticipated start date01/02/2007
Anticipated end date01/06/2008
Status of trialOngoing
Target number of participants144
InterventionsPurpose of Study:
This study is intended to improve the service available to patients attending hospital for chronic kidney disease (CKD). Many patients suffering from CKD will require some sort of kidney replacement therapy. Some may be fortunate enough to receive kidney transplant, however those that are not so fortunate will need dialysis of some kind. Dialysis is available in two ways: Peritoneal and Haemodialysis (HD). This study is concentrated on those preparing for HD. In order to begin dialysis a 'man-made' short circuit of the circulatory system must be created. This involves the connection of a vein to the side of an artery in the arm of the patient. This connection allows the development of the vein into a significantly larger vessel that allows easy needling during dialysis. This also means that the volume of flow through this connection, known as an arteriovenous fistula (AVF), also increases dramatically. It is this high blood flow that allows the patient to receive dialysis in just a few hours, when the flow of blood is reduced the time taken to dialyse is vastly increased. The development of these AVF is not always simple and they can often fail, sometimes only minutes after surgery. In order to improve the chances of survival we would like to investigate the protocols currently used to survey these AVF during development and assess the use of a new protocol and technique. Currently clinical assessment of the developing AVF occurs around two weeks post operation. Any problems identified at this stage mean the patient can be referred for an alternative investigation. This alternative investigation is duplex ultrasound. Evidence supports ultrasounds ability to identify accurately any abnormality in the developing AVF without the need for an invasive technique. This study aims to compare the ability of clinical assessment and ultrasound to accurately predict the outcome of a developing AVF. Whilst doing this we intend to identify the most accurate time for ultrasound surveillance of the developing AVF.

Methodology
Consented patients will be randomly allocated to one of two groups:
Group 1: Clinical assessment
Group 2: Ultrasound assessment

Patients in both groups will be seen in the vascular laboratory for a pre access vein map to be produced. This allows the surgeon to choose the optimum location for the AVF to be created. It will also reduce the chance for bias towards those patients that require pre-access vein mapping as a result of an inconclusive clinical assessment.
Group 1: These patients will be seen by Tessa Savage (renal coordinator) to perform a clinical assessment of the developing AVF on two occasions, firstly 2 weeks post operation and secondly; 6 weeks post operation. Should any abnormality be identified by the clinical assessment then the patient will enter the normal pathway of care.
Group 2: These patients will be seen by Matthew Bell (clinical vascular scientist) to perform a duplex ultrasound surveillance scan. This scan will occur on five occasions: immediately post operation whilst still an inpatient, 1 week post operation (outpatient), 2 weeks post operation (outpatient), 4 weeks post operation (outpatient) and 6 weeks post operation (outpatient).
Should patients in either group become concerned about the development of the AVF outside of the appointment times then they will be encouraged to contact either Matthew Bell or Tessa Savage to arrange further examination.
Primary outcome measure(s)1. The specificity and sensitivity of both clinical assessment and ultrasound in predicting AVF success or failure
2. ROC curves will be used to identify the most accurate ultrasound criteria found for predicting AVF failure or success
3. ROC curves will also be used for identifying the optimum time for ultrasound surveillance.
Secondary outcome measure(s)Not provided at time of registration
Sources of fundingNorth Bristol NHS Trust

Sponsor nameRecord Provided by the NHSTCT Register - 2007 Update - Department of Health
Sponsor detailsThe Department of Health, Richmond House, 79 Whitehall
London
United Kingdom
SW1A 2NL
Sponsor telephone+44 (0)20 7307 2622
Sponsor fax+44
Sponsor emaildhmail@doh.gsi.org.uk
Sponsor websitehttp://www.dh.gov.uk/Home/fs/en
Contact nameMr Matthew Bell
Contact detailsSouthmead Hospital
Westbury on Trym


Bristol
United Kingdom
BS10 5NB
Contact telephone+44 01179596363
Contact fax+44 07880541209
Contact emailmatthew.bell@nbt.nhs.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN54883610
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol Top studies in medical research Submit to Trials journal
terms & conditions | privacy statement | © Current Controlled Trials Ltd


BioMed Central